CV Sciences Inc (CVSI)

[jefra1965]

CVSI TTM Powerful Numbers (Trailing 12 Months) Update: Aug 16
Price: $5.61

Sales $33.25M (Up 137.6%) & Trending UP
GM 71.7% or $23.85M & Trending UP
Oper. Exp. 46.6% and improving
Net Profit $3.7M or 11.17%
EPS = $0.04 & Trending UP
PE = 140.25
Estimated EPS FY2018: $0.16-$0.19
Free Cash Flow $8.14M or 24.48% (A CASH COW already) & trending UP.
Cash $7.2M
Work Cap. $11.24M
Debt $850K (Non convertible)
P/S Valuation = 15.34
P/S Valuation Indu. average (Best Companies) = Well above 25 (Estimated)
_______________________________________________
https://globenewswire.com/news-release/2018/07/23/1540604/0/en/CV-Sciences-Inc-Files-Application-for-Up-Listing-to-the-NASDAQ-Capital-Market.html
https://soundcloud.com/newcannabisventures/the-drivers-behind-cv-sciences-breakout-quarter-of-123-million-in-cbd-sales
https://www.businessinfocusmagazine.com/2016/03/bringing-cbd-to-the-mainstream/
https://emerginggrowth.com/cv-sciences-otcqb-cvsi-this-hot-cbd-stock-is-a-buy-and-hold-despite-bumpy-ride-to-nasdaq/
https://www.youtube.com/embed/aq4--rIolls
_____________________________________________
Quote:
Going forward, we are very optimistic about the growth potential for the hemp CBD product category. Industry forecasts estimate that the hemp CBD product category will reach nearly $1.6 billion by 2021(8.4 Times).

While not providing specific guidance, we believe our strong growth will continue, including our ability to generate profitable sales and cash flow. We believe the hemp CBD product category will continue to expand and our ability to grow as the market leader is well-positioned.

The first six months of 2018 have been a great start to the year for our company and we are confident in our ability to deliver a strong second-half to 2018 and believe that we can continue this growth momentum in 2019 and beyond.
__________________________________________________________
2017 Hemp CBD market sales was $190M. CVSI sold $20.7M

https://www.facebook.com/pluscbdoil/videos/1974202205985123/
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm
https://ir.cvsciences.com/press-releases/detail/73/cv-sciences-inc-announces-landmark-publication-on-the
https://www.wthr.com/article/new-labeling-rules-now-effect-all-cbd-oil-sold-indiana
https://ir.cvsciences.com/press-releases/detail/81/world-renowned-neurosurgeon-health-and-nutrition-expert
https://www.endurancebusiness.com/2018/industry-news/snaac-cbd-launched-as-industrys-first-hemp-based-cbd-sports-bar/
https://www.hindawi.com/journals/jt/2018/8143582/
https://twitter.com/PlusCbdJapan
_________________________________________
Drug development segment:

CV Sciences CFO, Joseph Dowling, discussed the Company's initial drug candidate (CVSI-007),
How CVSI-007 works..

Catalysts for next 3 months :
- Plus CBD selling in Japan https://twitter.com/PlusCbdJapan
- Hemp legalization in US (Highly possible)
- DEA rescheduling CBD (Highly possible)
- Canada starts marijuana legalization
- mid term election. Many states have ballots for marijuana

Other Catalysts:
-GRAS certification https://www.fda.gov/food/ingredientspackaginglabeling/gras/
-potential for new products ( New trademarks on the work)
-potential for PRs touting additional stores
-next Q report (early November)
-up-list updates
-CV-007 IND (early 2019)
_________________________________________________
Explaining the $4.00 Bid price, or the $2.00 - $3.00 minimum closing price for up-listing

Refer to the table in page 10 (Nasdaq Capital Market
Financial and Liquidity Requirements) of the following link:
https://listingcenter.nasdaq.com/assets/initialguide.pdf

At the bottom of the table is written:

Quote:

* Currently traded companies qualifying solely under the Market Value Standard must meet the $50 million Market Value of Listed Securities and the applicable bid price requirement for 90 consecutive trading days before applying.
** To qualify under the closing price alternative, a company must have: (i) average annual revenues of $6 million for three years, or (ii) net tangible assets of $5 million, or (iii) net tangible assets of $2 million and a 3 year operating history, in addition to satisfying the other financial and liquidity requirements listed above.


Conclusion: It is clear that CVSI meets all the criteria under the "Equity Standard" requirements and qualifies under the closing price alternative. The minimum closing SP must be $3.00 and does not need to wait 90 days. The timeline is by the end of August or first week in September